Interview with Swee-Yeok CHU, CEO & President, EDBI/Bio One Capital
As the CEO of EDBI since late 2008, what would you say have been the main developments of the agency during this time? EDBI is the strategic corporate investment arm…
Address: 2 Chia Ping Road, # 09-01 Singapore 619968 ,Singapore
Tel: +65 6265 2777
Web: http://www.dha.asia/
Drug Houses of Australia Pte Ltd. (DHA) is a subsidiary of Watson Pharmaceuticals, Inc., New Jersey, USA., and operates an extensive network of pharmaceutical business operations in Southeast Asia. Watson Pharmaceuticals, Inc. is a leading integrated generic pharmaceutical company grossing a revenue of USD4.6 billion in 2011, and currently has operations spread across the globe.
DHA has already become a household name, with a strong brand build upon premium products, manufactured at their own facilities in Singapore and at other global sites via contract manufacturing. They ensure consistent high quality and reliability in every single product, and their manufacturing sites include those approved by stringent requirements of regulatory authorities such as USFDA, TGA & MHRA
Generic Drugs
As the CEO of EDBI since late 2008, what would you say have been the main developments of the agency during this time? EDBI is the strategic corporate investment arm…
What prompted you to found TriReme six years ago? I set up companies, so TriReme was not the first. The idea behind TriReme was to provide solutions for complex cases,…
Singapore wants to be seen as a springboard for Asia, but that is a position that other countries in Asia would also like to hold. In general, executives prefer to…
Since the last time we had the pleasure of meeting you, 4 years ago, what have been the main developments and changes in the Singaporean pharmaceutical industry? One of the…
Central Asia, what is Central Asia in the BD perspective? For us, Central Asia includes all the countries in Asia, except Greater China, India and Japan. What have been the…
The company’s current corporate strategy includes a major focus on the Emerging Markets and Asia Pacific (EMAP) region. Concretely, what are the expectations and the main objectives for the Asia…
Please give us an overview of HOYA Surgical Optics and its operations. HOYA Surgical Optics is a global manufacturer of intraocular lenses (IOLs) — the artificial lens that is put…
There has been much hype about emerging markets, especially those in Asia. How important are these markets for GE and what are your respective goals for the next three years?…
As a pioneering member of Arcasia, before it merged with JTC International and became what is Ascendas today, you know the history of the company very intimately. What are the…
In Q3 2012, MSD reported worldwide sales of $11.5 billion. What was the contribution that emerging markets had? From an MSD perspective, emerging markets refer to every market outside North…
Pfizer completed the acquisition of Wyeth three years ago. How did the merge impact the Singaporean operations? As the result of the merge, Pfizer in Singapore has been able to…
Prior to joining AMRI you worked in diverse companies in Japan, like Dishman, Pfizer and Bayer. What attracted you to this company? The main reason is that Singapore has growing…
See our Cookie Privacy Policy Here
